Skip to main content

Table 1 Summary of Clinical, Pathologic and Genetic Characteristics of Tumors

From: KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma

Timeline Location Diagnosis Immunophenotype of Neoplastic Cells Key FISH/Molecular Characteristics Therapy
Year 1 Neck mass FL (Fig. 1) CD19+, CD10+, CD5-, surface lambda restricted NA Radiation
Year 3 Lung and bone marrow Lung: DLBCL
Bone marrow: FLĀ (Fig. 2)
Lung: CD20+, CD10+
Bone marrow: CD19+, CD10+, CD5-, surface lambda restricted
NA R-CHOP
Year 9 Skin and breast FL (Fig. 3) CD20+, CD10+, BCL6+, BCL2+ IgH/BCL2 fusion
KRAS wildtype
MYC extra copies; no MYC rearrangement
R-Bendamustine
Year 10 Inguinal lymph node LCS (Fig. 4) CD45+, CD43+, CD1a+, S100+, CD20-, PAX5-, CD19-, CD79a-, CD10-, BCL6+ (focal) IgH/BCL2 fusion
KRAS p.G13D
MYC extra copies; no MYC rearrangement
ICE, ibrutinib
Year 10 Ear mass DLBCL CD20+, CD10+, CD1a-, S100- NA Palliative radiation therapy
  1. FL Follicular Lymphoma, LCS Langerhans Cell Sarcoma, DLBCL Diffuse Large B cell Lymphoma, NA Tissue Not Available